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What Is Dementia
Dementia, in which parts of the brain stop working, occurs more frequently as people age. As a result, in societies where life expectancy has been extended, dementia is one of the most severe health problems of the aging populations. Approximately 15 percent of the people who live to the age of 65 will show some symptoms of dementia and there are currently about 18 million people with dementia in the world. The number of people with dementia is expected to increase globally to about 34 million by 2025. 1) Symptoms of dementia include:
• loss of memory • difficulty in finding the right words or understanding what people are saying • difficulty in performing previously routine jobs • personality and mood changes The most common cause of dementia is Alzheimer's disease (AD), which accounts for 55% of all dementia patients worldwide. The second cause of dementia is vascular dementia (VD), which makes up 20% of all cases. VD used to be the most common cause of dementia in Japan. However, the proportion of AD patients has been increasing yearly and AD is now the leading cause of dementia in Japan.
2) Consequently, it is important to introduce new therapeutic agents for AD in order to alleviate dementia.
About Alzheimer's Disease
AD, a neurodegenerative disorder discovered by Alois Alzheimer in 1907, is characterized by a progressive deterioration of memory and cognition.
3) Neuropathologically, AD is identified by three major signs: amyloid-b plaques (Ab), neurofibrillary tangles (NFT) and synaptic loss. 4) In particular, the degeneration of cholinergic neurons in the cortex and hippocampus and a loss of acetylcholine (ACh), a neurotransmitter for cholinergic neurotransmission, in the brain are characteristically observed in AD patients. 5 ) So far, no single factor causing AD has been identified, but it is likely the result of a combination of factors, such as age, genetic makeup, or environmental factors. 6) 
Treatment of Alzheimer's Disease
A deficiency in cholinergic neurotransmission is considered to play an important role in the learning and memory impairment of AD patients. Recent progress in the understanding of the pathology of Alzheimer disease has made it possible for potential disease-modifying therapies to be tested in clinical trials. [7] [8] [9] [10] [11] However, no such therapy is available at present. Therefore, cholinergic enhancement remains the most effective therapeutic method to treat AD. 12) In the course of neurotransmission at cholinergic synapses ( Fig. 1) , ACh is released from the presynapse into the synap- tic cleft and binds to muscarinic and nicotinic receptors on the postsynapse. This nerve impulse transmission at cholinergic synapses is terminated by acetylcholinesterase (AChE) which catalyzes the hydrolysis of ACh.
Development of an Efficient
To date, several strategies have been explored on the basis of the above neurotransmission mechanism in order to enhance cholinergic functions.
These are: [1] AChE inhibitors, 13) which increase the level of ACh in the synaptic cleft [2] ACh precursors, 14) such as choline [3] ACh releasers, 15) which advance the release of ACh from presynapses [4] muscarinic agonists, 16) which activate muscarinic receptors on postsynapse [5] nicotinic agonists, 17) which activate nicotinic receptors on postsynapse Among these strategies, it is known that the only clinically effective strategy for the palliative treatment of AD is to inhibit AChE. 18) At present, several AChE inhibitors have successfully reached the market, such as tacrine (Cognex ® ), 19) donepezil (Aricept ® ), 20) rivastigmine (Exelon ® ) 21) and galanthamine (Reminyl   ®   ) 22) (Fig. 2 ). Tacrine (Cognex ® ), a reversible AChE inhibitor, was the first approved drug for AD from Warner-Lambert. It can improve some of the symptoms of AD patients. However, it also causes a potentially serious side effect, liver damage. Donepezil (Aricept ® ), a reversible AChE inhibitor, was produced by Eisai. It has now replaced tacrine because of its convenient once-a-day administration (tacrine, four times daily). In addition, it does not cause hepatotoxic effects. Ri- These drugs do not provide a complete cure, but stabilize some of the symptoms of AD patients for a limited time. However, the usefulness of these AChE inhibitors in a clinical setting is limited mainly due to their adverse effects on peripheral organs, since ACh works as the primary neurotransmitter in the body as well as in the brain. 24) 
Narihiro

Structure of Acetylcholinesterase
Sussman et al. reported on the determination of the crystal structure of AChE from Torpedo californica by X-ray analysis to 2.8 angstrom resolution.
25) The AChE enzyme is an a/b protein that contains 537 amino acids forming of 12b-sheets surrounded by 14a helices. A catalytic triad consisting of Ser200, His400 and Glu327, is located at the bottom of a deep and narrow gorge. The gorge is lined with the side chain rings of 14 aromatic residues.
With respect to donepezil, complex structure models and their binding interactions were simulated by molecular modeling methods. 26) Recently, Susmman et al. solved the complex crystal structure of donepezil with Torpedo californica AChE and reported three major binding interactions: the benzyl moiety to Trp84 at the bottom of the gorge; the charged nitrogen of the piperidine ring to Phe330 in the middle of the gorge; and the indanone ring to Trp279 at the top of the gorge (Fig. 3) . 27) These studies provide some useful information on, for example, inhibitor-enzyme interactions and possible binding sites, for the design of potent AChE inhibitors.
Depression in Alzheimer's Disease
Recent studies suggest that cholinergic dysfunction does not completely explain age-related cognitive deficits.
28) The hypofunction of several other neuronal systems such as the glutamatergic, (GABAergic and monoaminergic systems in the brain of AD patients may be partly responsible for this cognitive decline. 29) There are many experimental reports suggesting that several neurotransmitters, including serotonin, norepinephrine, dopamine and g-aminobutyric acid (GABA), appear to play a role in cognitive processes and interact with the cholinergic systems. 30) Moreover, AD patients often exhibit a number of behavioral abnormalities, such as irritability, anxiety and depression, as well as cognitive impairment. 31) These psychiatric symptoms are sometimes controlled by psychotropic agents. 32) Among these symptoms, it is most often reported that depression is present in about 40% of patients with dementia. 33) Currently, depression in AD patients has been successfully treated with serotonin transporter (SERT) inhibitors, 34) a type of antidepressant which has no anticholinergic side effect, since serotonin is known to be a neurotransmitter associated with many psychiatric symptoms including depression. Currently, the most commonly used treatments for depression in AD patients are SERT inhibitors such as fluoxetine 35) and paroxetine 36) which have no anticholinergic side effects (Fig. 4) . At serotonergic synapses, serotonin is released in the brain synaptic cleft and binds to a receptor. Upon its reuptake into the presynaptic neuron by SERT, which terminates the action of serotonin, it is recycled into the neurotransmitter pool (Fig. 5) . Therefore, inhibition of SERT results in an increased concentration of serotonin in the brain synaptic cleft, i.e. an enhanced serotonergic neurotransmission.
Concept of Dual Inhibitors of AChE and SERT as Therapeutic Agents for Alzheimer's Disease
To date, AChE inhibitors are able to enhance memory in AD patients, but their clinical efficacy is limited mainly due to their adverse peripheral effects. 37) SERT inhibitors which have no anticholinergic side effects are also useful for controlling depression in AD patients. However, co-administration of SERT and AChE inhibitors would be undesirable due to the difficulty in managing their different pharmacodynamic and pharmacokinetic properties. Moreover, it may cause harmful drug-drug interactions as well. 38) In order to overcome these disadvantages, a drug inhibiting both SERT and AChE but in a balanced manner is considered to be a promising method. This combined SERT and AChE inhibition would bring about greater therapeutic benefits than AChE inhibition alone, since further improvement of cognitive deficits could be achieved without the doserelated adverse effects caused by excessive AChE inhibition. Thus, AChE-SERT dual inhibitors would be a novel class of anti-AD drugs that are more effective in alleviating the symptoms of AD than known AChE inhibitors (Fig. 6) .
So far, only two groups have studied AChE inhibitors that also possess SERT inhibitory activity. Hirai et al. reported that 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate (TAK-147) showed potent AChE inhibition (IC 50 ϭ51 nM) (Fig. 7) . Furthermore, it weakly inhibited noradrenaline transporter and SERT (IC 50 ϭ4020 and 1350 nM, respectively). 39) McKenna et al. reported that several analogues of tacrine could be useful templates for further investigation of dual AChE and SERT inhibitors (Fig. 7) . 40) The compounds described by these two groups showed potent AChE inhibitory activities and moderate SERT inhibitory activities in vitro. However, the extent of inhibition against each was imbalanced when it came to in vivo dual inhibition. Consequently, no antidepressive effect resulting from SERT inhibition was observed due to the dominating effect of increased cholinergic transmission. Recently AChE inhibitors such as protopine and S-9977 reportedly have SERT inhibitory activity, although involvement of those activities in clinical efficacy has not been elucidated yet. 41, 42) It is clear that the balance between AChE and SERT inhibition is crucial for the simultaneous activation of the cholinergic and serotoninergic transmissions in the brain in vivo. Therefore, the creation of a balanced dual inhibitor of AChE and SERT, one that can achieve the same pharmacological effects as those observed in vivo, is challenging but necessary.
Design of AChE and SERT Dual Inhibitors
On the basis of the X-ray structure of the complex of AChE and donepezil and molecular modeling studies, we proposed a hypothetical model explaining the inhibition mode at the active site of AChE, which involves four binding sites (Chart 1). In order to design a dual inhibitor, we selected rivastigmine, one of the marketed AChE inhibitors, as a lead compound. Rivastigmine has three binding elements for the hypothetical binding sites of AChE, and they are:
(1) a carbamate group to the catalytic triad site (2) an aromatic group to hydrophobic binding site A (3) an amine group to the ionic site Focusing on the fourth binding site of the hypothetical model, fluoxetine, an antidepressant, was chosen as the pharmacophoric element that would bind to hydrophobic binding site B. Fluoxetine has potent inhibitory activity against SERT and possesses an ethylamine moiety that could be overlapped with that of rivastigmine. Therefore, a type A compound designed by hybridizing of these two compounds at their common ethylamine moiety was expected to be a dual inhibitor of AChE and SERT.
Synthesis of Type A Derivatives
Firstly, various type A derivatives were synthesized for optimization of their inhibitory activities as AChE-SERT dual inhibitors. 43) The preparation of meta-carbamate derivatives 4a-f and para-carbamate derivatives 5a-j is shown in Chart 2. Onepot condensation 44) of hydroxybenzaldehyde 1, malonic acid and methylamine, followed by esterification of the carboxylic acid catalyzed by sulfuric acid and the tert-butoxycarbonyl (Boc) protection of methylamine provided compound 2. Compound 2 was treated with dimethylcarbamyl chloride, followed by reduction of the ester group with LiAlH 4 to furnish primary alcohol 3. Primary alcohol 3 was etherified with various phenols, followed by deprotection of the Boc group with 2 N HCl in ethyl acetate to give compounds 4a-f and 5a-j.
The synthesis of both enantiomers of 5j was described in Chart 3. The primary amine of known (S)-6 45) was Boc-protected, followed by treatment with dimethylcarbamyl chloride to afford (S)-7. Reduction of the ester group of (S)-7 with LiAlH 4 gave primary alcohol (S)-8. The alcohol (S)-8 was reacted under Mitsunobu reaction conditions with p-nitrophenol, followed by methylation of the Boc-protected amine with iodomethane. Finally, deprotection of the Boc group with 2 N HCl provided (S)-5j. Enantiomer (R)-5j was prepared by the same method starting from (R)-6.
Results of Type A Derivatives
All the final compounds were tested for in vitro inhibition of AChE from mouse brain and SERT from rat synaptosome. The protocols used here are described in the Experimental section. Table 1 summarizes the inhibitory activities of compounds 4a-f, which possess the dimethylcarbamate at the meta position similar to rivastigmine. For comparison, the assay data of rivastigmine, donepezil and fluoxetine are also included. The effect of the electron-donating (4a, b) and electron-withdrawing (4c-f) substituents X at the 4-position of the phenyl ether moiety was examined. Nearly all of the 4-substituted derivatives 4a-e exhibited potential inhibitory activity against SERT (IC 50 Ͻ50 nM) but much lower activity against AChE (IC 50 Ͼ1000 nM). However, only the 4-nitrosubstituted derivative 4f was found to be a potential dual inhibitor of AChE (IC 50 ϭ221 nM) and SERT (IC 50 ϭ52 nM).
Changing the location of the dimethylcarbamate from the meta position to the para position mostly increased the potency against AChE, but decreased the potency against SERT ( Table 2 ). Among the compounds 5a-j, the 4-nitro-substituted derivative 5j was revealed to possess good potencies against both AChE (IC 50 ϭ125 nM) and SERT (IC 50 ϭ44 nM), inhibiting them both to a suitable extent.
The effect of the carbamate moiety in 5j was examined (Table 3 ). The carbamate derivatives 9a, b had good anti-SERT activity but moderate anti-AChE activity. The dimethylamide derivative 9d 43) no longer exhibited an inhibitory effect against AChE, whereas its anti-SERT activity was maintained. The removal of the dimetylcarbamyl moiety from 5j led to a loss of the inhibitory activities against both AChE and SERT (7c). These results suggest that the dimethylcarbamate moiety is essential for anti-AChE activity.
The optimization of the methylamine moiety in 5j is shown in Table 4 . The dimethylamine derivative 10a was found to be less potent than 5j. Increasing the size of the amine (10c-g) resulted in a sharp decline of inhibitory potencies against both AChE and SERT. Ammonium derivative 10b was found to have lost its inhibitory activities against AChE (IC 50 Ͼ1000 nM), whereas the potency against SERT was maintained (IC 50 ϭ44 nM). In general, it seems that a small amine like methylamine is particularly favorable for dual inhibition of AChE and SERT. 46) As shown in Table 5 , the effects of the tether length and the replacement of the hetero atom were examined. Compound 11 43) possessing a shorter tether length exhibited much less activity toward both AChE and SERT than 5j. However, compound 12 43) possessing a longer tether length displayed stronger activity against AChE (IC 50 ϭ77 nM) than 5j (IC 50 ϭ 125 nM) but lower potency against SERT (IC 50 Ͼ1000 nM). It seems that the nitrophenoxy moiety of compound 12 interacted more efficiently with the hydrophobic site B in our hypothetical model of the AChE active site than compounds 5j and 11. The replacement of oxygen by nitrogen (13, 14) or sulfur (15) resulted in a reduction of inhibitory potency particularly against SERT. Compound 16, in which the ethereal oxygen was removed from 5j, was found to be a moderate dual inhibitor of AChE (IC 50 ϭ524 nM) and SERT (IC 50 ϭ670 nM). These replacement studies revealed that the ethereal oxygen was crucial for the inhibition of both AChE and SERT.
Since we stated that racemic 5j was the best dual inhibitor of AChE and SERT, both enantiomers of 5j were evaluated ( Table 6 ). Compound (S)-5j showed potent inhibitory potencies against both AChE (IC 50 ϭ101 nM) and SERT (IC 50 ϭ 42 nM). There was little difference in AChE inhibitory activity between the stereoisomers of 5j. However, SERT inhibition of (S)-5j was 3-fold more potent than that of (R)-5j.
Synthesis of Type B Derivatives
For further development of dual AChE and SERT inhibitory activities, conformationally restricted type B derivatives were designed by linking the methylamine moiety and the ortho-carbon atom of the phenyl ring of (S)-5j with a carbon chain of appropriate length (Fig. 8) .
47)
Preparation of the 1,2,3,4-tetrahydroisoquinoline derivatives (nϭ0) using a Bischler-Napieralski reaction is shown in Chart 4. Methoxyphenethylamine 17 was treated with ethyl malonyl chloride to give an N-acylated compound. The 1,2,3,4-tetrahydroisoquinoline skeleton was constructed by a Bischler-Napieralski reaction using POCl 3 
Chart 5 shows the synthesis of the rigid derivatives having a saturated (35a, b and 36a, b) or unsaturated (32a, b and 33a-h) seven-membered ring (nϭ1). We formed the sevenmembered ring by a ring-closing olefin metathesis reaction, 48) which is a very effective method for making rings of various sizes. Treatment of dihydroxybenzaldehyde 26 with dimethylcarbamyl chloride using sodium hydride or pyridine selectively provided a mono-carbamate product. The remaining phenol was converted to an aryl triflate by treatment with The asymmetric synthesis of (R)-33a is shown in Chart 6. Phenol 37 49) was protected with a methoxymethyl (MOM) group and a Horner-Wadsworth-Emmons reaction provided a,b-unsaturated ester 38. Compound 38 was subjected to chiral amination by a method reported by Davies and Walters.
50) The resulting amine was protected with a Boc group to furnish (R)-40 (99% ee). (ii) (CH 2 ϭCH)(n-Bu) 3 Sn, Pd(PPh 3 ) 4 , LiCl, dioxane, 100°C, 86% (2 steps); (k) allyl bromide, NaH, DMF, 0°C to rt, 86%; (l) 30 (10 mol%), CH 2 Cl 2 (15 mM), 45°C, 96%; (m) 2 N HCl-AcOEt, rt, 96%; (n) (i) 37% HCHO aq., HCO 2 H, 80°C, 78%.
Chart 6
Grubbs 2nd generation catalyst 30 provided a seven-membered ring product. Deprotection of the Boc group and Eshweiler-Clarke methylation furnished (R)-33a. The enantiomer (S)-33a was prepared by the same method using chiral amine (R)-39.
The absolute configuration of (R)-40 was determined as shown in Chart 7. Triflate (R)-44, which was prepared by triflation of (R)-42, was converted to (R)-45 by treatment with a catalytic amount of Pd(OAc) 2 in N,N-dimethylformamide (DMF). All the physical properties, including the optical rotation of (R)-45, were identical to those of the authentic sample, which was prepared from known compound (R)-8. Table 7 summarizes the inhibitory activities against AChE and SERT of the conformationally restricted derivatives containing a 1,2,3,4-tetrahydroisoquinoline skeleton (21a, b,  22a, b, 23, 24a-g and 25a, b) . 1,2,3,4-Tetrahydroisoquinoline derivatives were reinvestigated with respect to substituent X using, in particular, an electron-withdrawing group, and the ideal carbamate position. A series of 1,2,3,4-tetrahydroisoquinoline derivatives were observed to have dramatically enhanced inhibitory activity toward AChE, but their inhibitory activity toward SERT had almost disappeared. We supposed that conformational restriction of the flexible amine moiety resulted in the appropriate binding to AChE. The reason for the disappearance of anti-SERT activity could not be determined because we had no information on the structure of SERT. Among the compounds with a 1,2,3,4-tetrahydroisoquinoline structure, 21a (RϭH, Xϭ4-NO 2 ) showed the most potent inhibitory activity against AChE (IC 50 ϭ8 nM).
Results of Type B Derivatives
Next, we examined the rigid derivatives 35a, b, 36a, b containing a saturated seven-membered ring and 32a, b, 33a-h containing an unsaturated seven-membered ring (Table 8) . Compounds 35a, b (RϭH) and 36a, b (RϭMe) showed higher inhibitory potencies against AChE but much lower potencies against SERT similarly to 1,2,3,4-tetrahydroquinoline derivatives. Compounds 32a, b (RϭH) which possessed a double bond on the seven-membered ring also exhibited good inhibitory activities but only against AChE, whereas compounds 33a-e (RϭMe) surprisingly showed potent inhibitory activities against not only AChE but also SERT. We have not determined the reason for this striking improvement in anti-SERT activities obtained by changing the secondary amine to a tertiary amine on the seven-membered ring. However, it is clear that the olefin moiety on the seven-membered ring is essential for the inhibitory potency of SERT as can be seen by comparing derivatives 33a-e with 36a, b. Compound 33a was the most potent dual inhibitor of AChE (IC 50 ϭ66 nM) and SERT (IC 50 ϭ63 nM). Changing the substitution position of the dimethylcarbamate from 7-to 6-(33f) and 8-(33g, h) resulted in the loss of inhibitory potency for SERT.
The inhibitory activities of both enantiomers of 33a were evaluated, as shown in Table 9 . The enantiomer (R)-33a showed extremely potent inhibitory activity against both AChE (IC 50 ϭ14 nM) and SERT (IC 50 ϭ6 nM). Although both 5j and its enantiomer showed similar levels of AChE inhibition, (R)-33a showed a 44 times stronger inhibitory activity against AChE than (S)-33a. This difference of AChE inhibition would result from the conformational rigidity of 33a. Similarly (R)-33a exhibited a 155 times stronger inhibitory activity against SERT than (S)-33a. Compound (R)-33a showed extremely weak inhibitory activities against butylcholinesterase, choline acetyltransferase, norepinephrine and dopamine transporters. Compound (R)-33a was an extremely potent inhibitor of both AChE (IC 50 ϭ14 nM) and SERT (IC 50 ϭ6 nM).
Docking Study of Dual AChE-SERT Inhibitors
A conformational analysis and a docking study of derivatives 5j, 11, 12 and 33a with AChE were performed in order to analyze their AChE inhibitory potencies. 51) Each compound was model-built using the QUANTA system 52) in the protonated form with respect to the basic amine. A conformational analysis using molecular dynamics and molecular mechanics was performed using the CHARMm force field. 53) A docking study of the inhibitors was carried out with the QUANTA/CHARMm system based on several low energy conformations obtained by the conformational analysis. A series of initial positions and conformations of the inhibitors were manually set and stable complex structures were obtained by energy minimization with the enzyme structure being fixed.
From the results, comparable interaction energies were obtained for (R)-5j and (S)-5j. This is consistent with the fact that only a slight difference was observed for the IC 50 values of the isomers of 5j. On the other hand, the interaction energy of the most stable model of (R)-33a was about 6 kcal/mol more stable than that of (S)-33a, which is consistent with the observed potencies of the isomers of 33a, i.e., (R)-33a is around 40 times more potent than (S)-33a.
The most stable complex structure models of (R)-33a and (S)-5j are shown in Figs. 9A and B. As it can be seen for both cases, the carbamate moiety was located near catalytic Ser200 and the phenyl ring was located in the hydrophobic pocket near Phe330, which is located deep in the gorge. The proton of the tertiary ammonium group did not interact directly with the carboxyl group of Asp72. The positive charge is considered to be stabilized by the aromatic ring of Tyr334 through an aromatic-ammonium interaction. 54) This kind of interaction is observed in several complex crystal structures, such as those of donepezil.
55) The 4-nitrophenoxy moiety was located near the indole ring of Trp279 at the top of the gorge.
In the case of compounds 5j, 11 and 12, the length of the methylene chain between the benzylamine and nitrophenoxy moieties is an important factor affecting the potency. Compound 11 with a shorter tether group showed very weak inhibitory activity (IC 50 Ͼ1000 nM). In contrast, compound 12 showed a slightly higher potency (IC 50 ϭ77 nM) than compound 5j (IC 50 ϭca. 100 nM). In order to explain the difference among 5j, 11 and 12, we focused on the position of the nitrophenoxy group at the binding site. The nitrophenoxy group of 5j was involved in the hydrophobic interaction with the indole group of Trp279 as mentioned above (Fig. 9A) . In the case of 11, the distance between the nitrophenoxy group and indole rings became 0.2 Å longer than that of (S)-5j (Fig.  9C) . The shorter tether for 11 would prevent both phenyl and nitrophenoxy groups to simultaneously interact with the hydrophobic pocket at the bottom and top of the gorge, respectively. On the other hand, the distance between the nitrophenoxy group of 12 and the indole ring of Trp279 was 0.4 Å shorter than that of (S)-5j, leading to an enlarged ring overlap (Fig. 9D) . Moreover, the interaction at the peripheral hydrophobic site seemed to be more favorable due to the additional hydrophobic methylene group of 12, even though its larger number of rotatable bonds was more disadvantageous with respect to entropy compared to 5j. This resulted in a slight improvement of the inhibitory activity of 12.
Pharmacological Effects of Dual AChE-SERT Inhibitors
The pharmacological properties of (S)-5j, the most potent type A compound, and (R)-33a, the most potent type B compound, were evaluated in order to show efficacy as a drug for AD. 56) In the experiments, (S)-5j was used as a (fumaric acid) 1/2 salt (RS-1259) for solidification and (R)-33a was used as a hydrochloride salt.
Ex Vivo Inhibition of AChE and SERT The result of the ex vivo inhibitory effects on AChE and SERT of RS-1259 in the mouse brain is shown in Fig. 10A . Table 10 summarizes the inhibition of AChE and SERT in mice and rats. The inhibition results of donepezil and fluoxetine are also included for comparison. After oral administration, compound RS-1259 inhibited both AChE and SERT in the mouse brains with a potency several fold weaker than donepezil and equiv- alent to fluoxetine, respectively. Compound (R)-33a, the most potent type B dual inhibitor, was not used in further experiments because a low penetration into the brain was predicted based on the ex vivo experiment of AChE inhibition in mice. The doses necessary for the 50% efficacy (ED 50 ) of RS-1259, donepezil and rivastigmine were larger in rats than those in mice, although the potency order of the compounds was the same in each species. RS-1259 was as potent as fluoxetine and more potent than fluvoxamine for SERT inhibition ex vivo in mice. RS-1259 is the first compound that can facilitate both cholinergic and serotonergic transmission in the brain following oral administration. The balanced inhibition of AChE and SERT by RS-1259 demonstrated the unique property of this compound and its potentially high efficacy in vivo. A single oral administration of RS-1259 inhibited AChE and SERT in the central nervous system in a similar time frame, as expected. After oral administration, RS-1259 inhibited AChE and SERT in the mouse brains in a similar manner over time. The inhibition of AChE and SERT which reached a maximum at 1-2 h, was still observed at 8 h and fully disappeared at 24 h after administration. The time to reach maximum AChE inhibition and the duration of the inhibitory effect of donepezil were much shorter than that of RS-1259 in mice (Fig. 10B) .
Microdialysis in the Rat Hippocampus An actual simultaneous elevation of extracellular levels of serotonin and ACh in the rat hippocampus due to the inhibition of both AChE and SERT was confirmed by microdialysis (Fig. 11) . RS-1259 simultaneously elevated extracellular levels of ACh and 5-HT in the hippocampus of freely moving rats. Donepezil and fluoxetine only increased ACh and 5-HT levels, respectively. ACh was increased to a similar extent by RS-1259 and donepezil at doses of 64 and 16 mg/kg, respectively. At such high doses, all the rats showed cholinergic symptoms such as muscle fasciculation, salivation and lacrimation. The rate of 5-HT increase induced by fluoxetine at a dose of 32 mg/kg was slower and the overall 5-HT values were lower than those by RS-1259 at 64 mg/kg. The flat body posture elicited by fluoxetine could not be distinguished from the abnormal posture resulting from the cholinergic symptoms which was observed when rats were treated with RS-1259.
Both the ex vivo measurements of AChE and SERT inhibition and the microdialysis experiment indicated that RS-1259 was 3-4 times weaker than donepezil and almost equipotent to fluoxetine in exerting central cholinergic and serotonergic effects, respectively.
5-Hydroxytryptophan (5-HTP)-Enhancement in
Mice RS-1259 enhanced 5-HTP-induced locomotor activity in a bell-shaped dose-response relationship with maximum enhancement at 8 mg/kg (Fig. 12A) . The locomotor activity in mice treated with doses larger than 8 mg/kg was reduced as the cholinergic symptoms appeared. Fluoxetine (Fig. 12B) and fluvoxamine (Fig. 12C) were effective in the test with a longer duration of action for fluoxetine than for fluvoxamine.
RS-1259 was as effective as the serotonin-selective re-uptake inhibitors in the 5-HTP enhancement test in mice, suggesting an anti-depressant effect could be expected with the compound. It was somewhat surprising that RS-1259 was effective at doses lower than the effective dose of fluoxetine, since the potencies of both compounds were similar in the ex vivo measurement of SERT inhibition in the brain. Such low doses of RS-1259 alone did not increase the locomotor activity in mice and fluoxetine-induced 5-HTP enhancement was not affected by a co-administration of donepezil at doses that do not induce cholinergic symptoms. The above inconsistency may be due to the difference in the pharmacokinetic properties between RS-1259 and fluoxetine. The doses of RS-1259 and donepezil eliciting similar increases of ACh in the hippocampus correlated well with their ED 50 for the ex vivo inhibition of brain AChE. An oral dose four times higher than donepezil was necessary for RS-1259 to achieve a similar inhibition level of brain AChE in mice and rats. Thus, it was concluded that the potency of RS-1259 following oral administration was approximately a quarter of that of donepezil with respect to AChE inhibition, whereas it was equipotent to fluoxetine with respect to SERT inhibition in the central nervous system in vivo.
Amelioration of Memory Deficits of Aged Rat It has been reported that not only cholinergic but also serotonergic impairments in the brain are involved in causing cognitive deficits in aged animals and in humans. 57, 58) The effectiveness of RS-1259 in improving these deficits related to the central nervous system was compared to that of donepezil by evaluating two models, i.e. memory deficits in aged rats and the daytime consciousness level of rats with nocturnal habits. Short-term memory is severely affected early on in the course of Alzheimer's disease as well as in the normal aging process, 60) and it is reported that short-term memory is preferentially impaired in aged animals. 61) To examine whether RS-1259 could improve age-related cognitive decline, the spatial short-term memory was evaluated by using a twoplatform task (TPT) using a water maze in aged rats. Briefly, two visible platforms of identical appearance (diameter: 12 cm), one fixed and the other floating, were simultaneously placed at the center of two non-neighboring quadrants (e.g. north and south) in the same pool as that in the pretraining. The surfaces of the platforms were set 0.5 cm above the water surface. The trial began by releasing a rat into the water facing the wall of the pool from one of the remaining two quadrants. The various patterns of platform locations and start positions are shown in Fig. 13A . One session consisting of 6 trials was given each day. The rats were released from the two start positions alternately and the trial ended when the rat reached either platform. At 24-25 months of age, 11 rats showing a significant decline in the TPT performance were orally administered AChE inhibitors or the vehicle 60 min before each test. In the first test, both donepezil (0.5 mg/kg) and RS-1259 (1 mg/kg, but not 0.5 mg/kg) significantly ameliorated age-related short-term memory impairment (Fig. 13B) . In the second test, at half the dose, donepezil (0.25 mg/kg) also improved the memory impairment, although at twice the dose (1 mg/kg) it did not (Fig. 13C) . A higher dose of RS-1259 (2 mg/kg) was also effective in recovering the memory deficit (Fig. 13C) . The parameters to evaluate sensorimotor acitivities, i.e. the swimming distance, the swimming speed, the floating time, and the swimming time of rats, were not affected by the drug treatments (data not shown).
Both RS-1259 and donepezil ameliorated the low TPT performance of aged rats, but the effective dose of RS-1259 was approximately four times higher than that of donepezil, suggesting that no advantage was obtained by a dual activation of cholinergic and serotonergic transmissions over a solely cholinergic activation in the brain with respect to memory enhancement. TPT is reported to be highly sensitive to cholinergic deficits. We failed to observe any increase in the extracellular levels of ACh and 5-HT in the rat hippocampus by fluoxetine and donepezil, respectively, even at high doses. A positive interaction between cholinergic and serotonergic transmissions in the central nervous system may not exist, at least not in the hippocampus. A higher TPT score by RS-1259 was probably obtained solely by improvements in the cholinergic transmission and not the serotonergic one. The simultaneous serotonergic activation by RS-1259 seemed not to affect the cholinergic transmission involved in the memory system.
Elevation of Daytime Consciousness Level in Rats
The daytime consciousness level of rats in a familiar cage was low. The total awake (10-20 min), slow wave sleep (35-45 min) and paradoxical sleep (about 5 min) episodes for every 60 min were stable during the recording period except for the initial 1 h when the awake episode increased and the other episodes decreased due to the handling necessary for oral administration. RS-1259 and donepezil, at all doses tested, increased the awake episode and decreased slow wave sleep as well as paradoxical sleep episodes in the initial 1 h following oral administration (Fig. 14) . The consciousness level remained elevated up to 3 h after the highest dose of RS-1259 was administered, whereas it returned to control levels after 2-3 h in rats given the highest dose of donepezil. RS-1259 was also effective for the elevation of the daytime consciousness level in rats where the serotonergic neurons in the brain had been degenerated by an intracerebroventricular injection of 5,7-dihydroxytriptamine (5,7-DHT), except for the minimum effective dose of 4 mg/kg (Table 11) . 62) No abnormal behavior was observed throughout the recording period at any dose tested.
The consciousness level is associated with several neurotransmitter systems in the brain, including the cholinergic and serotonergic systems. Dringenberg and Diavolitsis reported that co-activation of the cortical cholinergic and 63) The authors used a complicated pharmacological procedure to induce the blockade and a co-activation of cholinergic and serotonergic transmissions in the cortex, without considering any possible drug-drug interaction between the compounds used. Using the dual inhibitor of AChE and SERT, we were able to evaluate the pharmacological effects of a simultaneous activation of both cholinergic and serotonergic transmissions in the brain without having to take into account any drug-drug interaction. We compared the effect of RS-1259 with that of donepezil on the daytime consciousness level of rats, which is low when they are in a familiar surrounding. Both compounds increased the consciousness level at similar doses. Considering the fact that RS-1259 inhibited brain AChE with a potency four times weaker than that of donepezil, this result clearly indicates that a simultaneous activation of the central serotonergic system could reduce the dose of AChE inhibitor needed to maintain an active consciousness level. This notion was confirmed by the observation that a larger dose of RS-1259 was required for elevation of the consciousness level in rats subjected to serotonergic denervation than that in normal rats.
It was confirmed that the degree of cholinergic activation required in maintaining the brain active could be reduced by a simultaneous activation of the central serotonergic transmission, using the dual AChE-SERT inhibitor.
Conclusion
Dual AChE and SERT inhibition is considered to be a highly effective method for treating AD because a reduction in the progress of cognitive decline could be achieved and dose-related adverse effects caused by excessive AChE inhibition could be avoided. To create dual AChE-SERT inhibitors, a hypothetical model of the AChE active center was conceived from the complex crystal structure of AChE and donepezil. Subsequently, a hybrid compound of rivastigmine and fluoxetine was designed as a novel dual AChE-SERT inhibitor.
As a result of structure-activity relationship studies, compound (S)-5j, which possessed balanced inhibitory activities of AChE and SERT, was successfully obtained. Moreover, conformationally restricted compounds of (S)-5j were designed for further improvement of inhibition potency. Among them, (R)-33a, which was successfully synthesized using a ring-closing olefin metathesis reaction, showed the strongest inhibition of both AChE and SERT as anticipated.
Molecular modeling studies of several compounds, including 5j and 33a, were performed to analyze their inhibitory activities against AChE. The results corresponded well with their potencies and provided some useful information about enzyme-inhibitor interaction.
We confirmed that the degree of cholinergic activation required to maintain an active brain could be reduced by a concurrent activation of the central serotonergic transmission, using the dual inhibitor RS-1259, an (S)-5j (fumaric acid) 1/2 salt. Thus, it was anticipated that cognitive disorders such as Alzheimer's disease could be effectively and safely treated with dual inhibitors of AChE and SERT. 64) BTG International Ltd. has been developing RS-1259 as BGC20-1259, the most promising inhibitor of AChE and SERT. BGC20-1259 has completed Phase I clinical studies in healthy volunteers and BTG recently announced that it will now be is exploring partnering opportunities for the programme. Numbers represent the mean of total time of awake episodes in the period of 180 min after a single oral administration of RS-1259, with the S.E.M. * pϽ0.05, * * pϽ0.01, vs. vehicle control in the intact rats. * * * pϽ0.01, vs. vehicle control in 5,7-DHT treated rats. The statistical differences were calculated in each group of intact and 5,7-DHT treated rats independently by a Dunnett's t-test.
